GlycoNex - About the company
GlycoNex is a public company based in Taipei (Taiwan), founded in 2001 by Tong-Hsuan Chang. It operates as a Developer of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies. The company has 436 active competitors, including 152 funded and 98 that have exited. Its top competitors include companies like BeiGene, Abcellera Biologics and Agios Pharmaceuticals.
Company Details
Developer of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies. The company’s technology platform enables glycosphingolipid antigen production and identification; monoclonal antibody production; cancer drug screening; stable cell line production for monoclonal antibody; and pharmacology/pharmacokinetics assessment.
- Email ID
- *****@glyconex.com.tw
Key Metrics
Founded Year
2001
Location
Taipei, Taiwan
Stage
Public
Ranked
132nd among 436 active competitors
Employee Count
28 as on Jul 31, 2026
Exit Details
Public
GlycoNex's IPO details
GlycoNex got listed on Dec 18, 2012.
Click here to take a look at GlycoNex's IPO in detail
Sign up to download GlycoNex's company profile
GlycoNex's funding and investors
GlycoNex is a funded company.
GlycoNex's founders and board of directors
Founder? Claim ProfileThe founders of GlycoNex is Tong-Hsuan Chang.
Here are the details of GlycoNex's key team members:
- Tong-Hsuan Chang: Founder of GlycoNex.
View details of GlycoNex's Founder profiles and Board Members
GlycoNex's employee count trend
GlycoNex has 28 employees as of Jul 26. Here is GlycoNex's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
GlycoNex's Competitors and alternates
Top competitors of GlycoNex include BeiGene, Abcellera Biologics and Agios Pharmaceuticals. Here is the list of Top 10 competitors of GlycoNex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd | Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
3rd | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
4th | TScan Therapeutics 1995, Boston (United States), Public | Developer of T cell therapies to harness the immune system against cancer | $180M | 70/100 | |
5th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
6th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
7th | Beijing Jiakesi drug development 2015, Beijing (China), Public | Developer of small molecule based therapeutics for cancer treatment | $55M | 67/100 | |
8th | Lyell Immunopharma 2018, San Francisco (United States), Public | Developer of CAR- T therapy for cancer treatment | $493M | 63/100 | |
9th | ABL Bio 2016, Seongnam-si (South Korea), Public | Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 63/100 | |
10th | Serum Institute of India 1966, Pune (India), Funding Raised | Manufacturer of vaccines and immuno-biological drugs for infectious diseases | - | 62/100 | |
132nd | Developer of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies | - | - | 41/100 |
Looking for more details on GlycoNex's competitors? Click here to see the top ones
GlycoNex's Investments and acquisitions
GlycoNex has made no investments or acquisitions yet.
Reports related to GlycoNex
Here is the latest report on GlycoNex's sector:
News related to GlycoNex
Media has covered GlycoNex for a total of 4 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
•
GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8PR Newswire•Jun 11, 2026•GlycoNex
•
GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC CandidateContract Pharma•Mar 23, 2026•GlycoNex, Nippon Kayaku
•
GlycoNex Signs CDMO Agreement with Change Cure to Advance HMGB1-Targeted Antibody ProgramBenzinga•Dec 08, 2025•GlycoNex, Change Cure
•
GlycoNex Announces Publication of Research Involving Pro-Antibody, GNX201PR Newswire•May 27, 2025•GlycoNex
•
GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab BiosimilarPR Newswire•Dec 17, 2024•GlycoNex
•
Glyconex Announces Manufacturing Agreement With Sterling For Gnx102-adc Clinical Trial ProductionPR Newswire•Nov 12, 2024•GlycoNex, Sterling Pharma Solutions
•
GlycoNex Enhances Global Intellectual Property Estate for GNX102 with Patent Approvals in Japan, South Korea, Russia and TaiwanPR Newswire•Jun 24, 2024•GlycoNex
•
GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADCPR Newswire•May 23, 2024•GlycoNex, Nippon Kayaku
•
GlycoNex Inc 4168 Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250Sectorpublishingintelligence•May 02, 2017•GlycoNex
Are you a Founder ?
FAQs about GlycoNex
Explore our recently published companies
- BIA Home Care Service - Pittsburgh based, 2021 founded, Unfunded company
- JK Auto & Truck Repair - Marlton based, Unfunded company
- Lippert - Elkhart based, 1956 founded, Unfunded company
- AMZ Tech Solutions - Cedar Rapids based, Unfunded company
- ItsGuru - Houston based, 2006 founded, Unfunded company
- Anh Totti Nguyen - Unfunded company